Acadia Pharmaceuticals

ACAD Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$22.20

-0.54% today

52W: $13.40 – $28.35

52W Low: $13.40 Position: 58.9% 52W High: $28.35

🔗 Compare Brokers

Key Metrics

P/E Ratio

9.65x

Price-to-Earnings

Forward P/E

24.54x

Forward Price/Earnings

P/S Ratio

3.53x

Price-to-Sales

EV/EBITDA

25.89x

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$3.8B

Market Capitalization

Revenue Growth

9.4%

YoY Revenue Growth

Profit Margin

36.49%

Net profit margin

ROE

39.89%

Return on Equity

Beta

0.83

Market sensitivity

Short Interest

7.88%

% of float sold short

Avg. Volume

1,679,719

Average daily volume

Valuation Analysis

Signal

Undervalued

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Buy

20 analysts

Avg. Price Target

$31.85

+43.47% upside

Target Range

$17.00 – $45.00

About the Company

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; A

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 796 Exchange: NMS